BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Annane D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux AL, Marchal A, Michelon H, Rottman M, Moine P; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 2020;28:100590. [PMID: 33173853 DOI: 10.1016/j.eclinm.2020.100590] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Hawley HB, Chang JC. Complement-Induced Endotheliopathy-Associated Vascular Microthrombosis in Coronavirus Disease 2019. J Infect Dis 2021;223:2198-9. [PMID: 33715011 DOI: 10.1093/infdis/jiab136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Christie MJ, Irving AT, Forster SC, Marsland BJ, Hansbro PM, Hertzog PJ, Nold-Petry CA, Nold MF. Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci Immunol 2021;6:eabd0205. [PMID: 34533977 DOI: 10.1126/sciimmunol.abd0205] [Reference Citation Analysis]
3 Stanevich OV, Fomina DS, Bakulin IG, Galeev SI, Bakin EA, Belash VA, Kulikov AN, Lebedeva AA, Lioznov DA, Polushin YS, Shlyk IV, Vorobyev EA, Vorobyeva SV, Surovceva TV, Bakulina NV, Lysenko MA, Moiseev IS. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study. BMC Infect Dis 2021;21:1277. [PMID: 34937556 DOI: 10.1186/s12879-021-06982-z] [Reference Citation Analysis]
4 Goshua G, Butt A, Lee AI. Immunothrombosis: a COVID-19 concerto. Br J Haematol 2021;194:491-3. [PMID: 34114208 DOI: 10.1111/bjh.17666] [Reference Citation Analysis]
5 Udovicic I, Stanojevic I, Djordjevic D, Zeba S, Rondovic G, Abazovic T, Lazic S, Vojvodic D, To K, Abazovic D, Khan W, Surbatovic M. Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. J Clin Med 2021;10:5815. [PMID: 34945111 DOI: 10.3390/jcm10245815] [Reference Citation Analysis]
6 Chang JC. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy. Vasc Health Risk Manag 2021;17:273-98. [PMID: 34103921 DOI: 10.2147/VHRM.S299357] [Reference Citation Analysis]
7 Das A, Behera LM, Rana S. Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of "Two-Site" Binding Paradigm. ACS Omega 2021;6:22876-87. [PMID: 34514259 DOI: 10.1021/acsomega.1c03400] [Reference Citation Analysis]
8 Felsenstein S, Reiff AO. A hitchhiker's guide through the COVID-19 galaxy. Clin Immunol 2021;232:108849. [PMID: 34563684 DOI: 10.1016/j.clim.2021.108849] [Reference Citation Analysis]
9 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
10 Kurtovic L, Beeson JG. Complement Factors in COVID-19 Therapeutics and Vaccines. Trends Immunol 2021;42:94-103. [PMID: 33402318 DOI: 10.1016/j.it.2020.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol 2021;164:69-82. [PMID: 34838588 DOI: 10.1016/j.yjmcc.2021.11.010] [Reference Citation Analysis]
12 Desvaux E, Hamon A, Hubert S, Boudjeniba C, Chassagnol B, Swindle J, Aussy A, Laigle L, Laplume J, Soret P, Jean-François P, Dupin-Roger I, Guedj M, Moingeon P. Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19. PLoS One 2021;16:e0254374. [PMID: 34293006 DOI: 10.1371/journal.pone.0254374] [Reference Citation Analysis]
13 Dawudi Y, Federici L, Debus J, Zucman N. Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab. BMJ Case Rep 2022;15:e242937. [PMID: 35487646 DOI: 10.1136/bcr-2021-242937] [Reference Citation Analysis]
14 Sattui SE, Crow MK, Navarro-Millán I. The role of immunomodulatory medications in the treatment of COVID-19. Curr Opin Rheumatol 2021;33:431-45. [PMID: 34397605 DOI: 10.1097/BOR.0000000000000817] [Reference Citation Analysis]
15 Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci 2022;29:1. [PMID: 34983527 DOI: 10.1186/s12929-021-00784-w] [Reference Citation Analysis]
16 Weckbach LT, Schweizer L, Kraechan A, Bieber S, Ishikawa-Ankerhold H, Hausleiter J, Massberg S, Straub T, Klingel K, Grabmaier U, Zwiebel M, Mann M, Schulz C; EMB Study Group. Association of Complement and MAPK Activation With SARS-CoV-2-Associated Myocardial Inflammation. JAMA Cardiol 2021. [PMID: 34910083 DOI: 10.1001/jamacardio.2021.5133] [Reference Citation Analysis]
17 Illouz T, Biragyn A, Iulita MF, Flores-Aguilar L, Dierssen M, De Toma I, Antonarakis SE, Yu E, Herault Y, Potier MC, Botté A, Roper R, Sredni B, London J, Mobley W, Strydom A, Okun E. Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. Front Immunol 2021;12:621440. [PMID: 34248930 DOI: 10.3389/fimmu.2021.621440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol 2021. [PMID: 34912108 DOI: 10.1038/s41577-021-00665-1] [Reference Citation Analysis]
19 Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol 2021. [PMID: 34759348 DOI: 10.1038/s41577-021-00634-8] [Reference Citation Analysis]
20 Shikdar S, Borogovac A, Mohamad E, Khawandanah M. COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab. Thromb J 2021;19:75. [PMID: 34674707 DOI: 10.1186/s12959-021-00330-6] [Reference Citation Analysis]
21 Zarubova J, Zhang X, Hoffman T, Hasani-Sadrabadi MM, Li S. Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases. Matter 2021;4:1528-54. [PMID: 33723531 DOI: 10.1016/j.matt.2021.02.025] [Reference Citation Analysis]
22 Otieno SB, Altahan A, Kaweeta F, Karri S, Alnoor F, Johnson R. Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol 2021;2021:6619177. [PMID: 34306774 DOI: 10.1155/2021/6619177] [Reference Citation Analysis]
23 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
24 Perico L, Morigi M, Galbusera M, Pezzotta A, Gastoldi S, Imberti B, Perna A, Ruggenenti P, Donadelli R, Benigni A, Remuzzi G. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Front Immunol 2022;13:827146. [DOI: 10.3389/fimmu.2022.827146] [Reference Citation Analysis]
25 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
26 Chouaki Benmansour N, Carvelli J, Vivier É. [Involvement of the complement cascade in severe forms of COVID-19]. Med Sci (Paris) 2021;37:333-41. [PMID: 33835019 DOI: 10.1051/medsci/2021021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D, Smyth SS, Parker WAE, Ajjan RA, Vilahur G, Badimon L, Berg JMT, Cate HT, Peyvandi F, Wang TT, Becker RC. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol 2022. [PMID: 35027697 DOI: 10.1038/s41569-021-00665-7] [Reference Citation Analysis]
28 Annane D. Corticosteroids for COVID-19. Journal of Intensive Medicine 2021;1:14-25. [DOI: 10.1016/j.jointm.2021.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Plášek J, Gumulec J, Máca J, Škarda J, Procházka V, Grézl T, Václavík J. COVID-19 Associated Coagulopathy: Mechanisms and Host-Directed Treatment. Am J Med Sci 2021:S0002-9629(21)00403-1. [PMID: 34752741 DOI: 10.1016/j.amjms.2021.10.012] [Reference Citation Analysis]
30 Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021;21:319-29. [PMID: 33824483 DOI: 10.1038/s41577-021-00536-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 33.0] [Reference Citation Analysis]
31 Annane D, Grimaldi-Bensouda L, Fremeaux-Bacchic V. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply. EClinicalMedicine 2021;35:100866. [PMID: 33937736 DOI: 10.1016/j.eclinm.2021.100866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 El Sissy C, Saldman A, Zanetta G, Martins PV, Poulain C, Cauchois R, Kaplanski G, Venetz JP, Bobot M, Dobosziewicz H, Daniel L, Koubi M, Sadallah S, Rotman S, Mousson C, Pascual M, Frémeaux-Bacchi V, Fakhouri F. COVID-19 as a potential trigger of complement-mediated atypical HUS. Blood 2021;138:1777-82. [PMID: 34482396 DOI: 10.1182/blood.2021012752] [Reference Citation Analysis]
33 Loh JT, Zhang B, Teo JKH, Lai RC, Choo ABH, Lam KP, Lim SK. Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes. Cytotherapy 2022:S1465-3249(22)00018-4. [PMID: 35177337 DOI: 10.1016/j.jcyt.2021.12.003] [Reference Citation Analysis]
34 Ghasemzadeh M, Ahmadi J, Hosseini E. Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis? Thromb Res 2022;213:179-94. [PMID: 35397313 DOI: 10.1016/j.thromres.2022.03.022] [Reference Citation Analysis]
35 Langford BJ, So M, Leung V, Raybardhan S, Lo J, Kan T, Leung F, Westwood D, Daneman N, MacFadden DR, Soucy JR. Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. Clin Microbiol Infect 2021:S1198-743X(21)00636-4. [PMID: 34843962 DOI: 10.1016/j.cmi.2021.11.008] [Reference Citation Analysis]
36 Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol 2021;51:1652-9. [PMID: 33738806 DOI: 10.1002/eji.202048959] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Haslbauer JD, Zinner C, Stalder AK, Schneeberger J, Menter T, Bassetti S, Mertz KD, Went P, Matter MS, Tzankov A. Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19. Front Immunol 2021;12:763098. [DOI: 10.3389/fimmu.2021.763098] [Reference Citation Analysis]
38 Plaçais L, Richier Q, Noël N, Lacombe K, Mariette X, Hermine O. Immune interventions in COVID-19: a matter of time? Mucosal Immunol 2021. [PMID: 34711920 DOI: 10.1038/s41385-021-00464-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, Bernardi FF, Racagni G, Berrino L, Castaldo G, Coscioni E, Rossi F, Capuano A. Therapeutic strategies to fight COVID-19: Which is the status artis? Br J Pharmacol 2021. [PMID: 33960398 DOI: 10.1111/bph.15452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Frémeaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front Immunol 2021;12:680567. [PMID: 34248962 DOI: 10.3389/fimmu.2021.680567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 2021;47:400-18. [PMID: 33893632 DOI: 10.1055/s-0041-1727282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
42 Fodil S, Annane D. Complement Inhibition and COVID-19: The Story so Far. Immunotargets Ther 2021;10:273-84. [PMID: 34345614 DOI: 10.2147/ITT.S284830] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Defendi F, Leroy C, Epaulard O, Clavarino G, Vilotitch A, Le Marechal M, Jacob MC, Raskovalova T, Pernollet M, Le Gouellec A, Bosson JL, Poignard P, Roustit M, Thielens N, Dumestre-Pérard C, Cesbron JY. Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality. Front Immunol 2021;12:742446. [PMID: 34567008 DOI: 10.3389/fimmu.2021.742446] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Caillon A, Trimaille A, Favre J, Jesel L, Morel O, Kauffenstein G. Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. J Thromb Haemost 2021. [PMID: 34672094 DOI: 10.1111/jth.15566] [Reference Citation Analysis]
45 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Delshad M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Poopak B, Shokouhi S, Bashash D. Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. Int Immunopharmacol 2021;99:107995. [PMID: 34304001 DOI: 10.1016/j.intimp.2021.107995] [Reference Citation Analysis]
47 Lim EHT, Vlaar APJ, de-Bruin S, Brouwer MC, van-de-Beek D. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key. EClinicalMedicine 2021;35:100722. [PMID: 33997737 DOI: 10.1016/j.eclinm.2021.100722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L, McGonagle DG, Machado PM. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Ann Rheum Dis 2021:annrheumdis-2020-219725. [PMID: 33589438 DOI: 10.1136/annrheumdis-2020-219725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
49 Pravdic Z, Mitrovic M, Bogdanovic A, Virijevic M, Sabljic N, Pantic N, Vukovic NS. COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria. Hamostaseologie 2021;41:397-9. [PMID: 34544179 DOI: 10.1055/a-1554-6432] [Reference Citation Analysis]
50 Leone VF, Imeraj A, Gastoldi S, Mele C, Liguori L, Condemi C, Ruggenenti P, Remuzzi G, Carrara C. Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. Front Pharmacol 2022;13:842473. [DOI: 10.3389/fphar.2022.842473] [Reference Citation Analysis]
51 Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front Immunol 2021;12:663187. [PMID: 33841446 DOI: 10.3389/fimmu.2021.663187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
52 Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL, Aschenbrenner AC. Neutrophils in COVID-19. Front Immunol 2021;12:652470. [PMID: 33841435 DOI: 10.3389/fimmu.2021.652470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
53 Sofia R, Carbone M, Landoni G, Zangrillo A, Dagna L. Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.04.009] [Reference Citation Analysis]
54 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Reference Citation Analysis]
55 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Senent Y, Inogés S, López-Díaz de Cerio A, Blanco A, Campo A, Carmona-Torre F, Sunsundegui P, González-Martín A, Ajona D, Okrój M, Prósper F, Pio R, Yuste JR, Tavira B. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge. Front Immunol 2021;12:767376. [PMID: 34868021 DOI: 10.3389/fimmu.2021.767376] [Reference Citation Analysis]
57 Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, Berger JS, Van Tassell BW, Middeldorp S, Piazza G, Weitz JI, Cushman M, Lip GYH, Goldhaber SZ, Bikdeli B. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost 2021. [PMID: 34538017 DOI: 10.1111/jth.15533] [Reference Citation Analysis]
58 Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, Kluge S, Diers A, Simon TP, Lautenschläger I, Gründling M, Jaschinski U, Simon P, Nierhaus A, Moerer O, Reill L, Jörres A, Guo R, Loeffler M, Reinhart K, Riedemann N. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor 2021;3:e0577. [PMID: 34806021 DOI: 10.1097/CCE.0000000000000577] [Reference Citation Analysis]
59 Vlaar APJ, Lim EHT, de Bruin S, Rückinger S, Pilz K, Brouwer MC, Guo RF, Heunks LMA, Busch MH, van Paassen P, Riedemann NC, van de Beek D. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci 2022. [PMID: 35029045 DOI: 10.1111/cts.13213] [Reference Citation Analysis]
60 Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, Hendricks O, Roccatello D, Stach K, Trunfio M, Vinet É, Schreiber K. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol 2021;3:e447-59. [PMID: 33817665 DOI: 10.1016/S2665-9913(21)00062-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]